125 related articles for article (PubMed ID: 23575960)
1. Knockout of the tetraspanin Cd9 in the TRAMP model of de novo prostate cancer increases spontaneous metastases in an organ-specific manner.
Copeland BT; Bowman MJ; Boucheix C; Ashman LK
Int J Cancer; 2013 Oct; 133(8):1803-12. PubMed ID: 23575960
[TBL] [Abstract][Full Text] [Related]
2. Genetic ablation of the tetraspanin CD151 reduces spontaneous metastatic spread of prostate cancer in the TRAMP model.
Copeland BT; Bowman MJ; Ashman LK
Mol Cancer Res; 2013 Jan; 11(1):95-105. PubMed ID: 23131993
[TBL] [Abstract][Full Text] [Related]
3. Deletion of PSCA increases metastasis of TRAMP-induced prostate tumors without altering primary tumor formation.
Moore ML; Teitell MA; Kim Y; Watabe T; Reiter RE; Witte ON; Dubey P
Prostate; 2008 Feb; 68(2):139-51. PubMed ID: 18044730
[TBL] [Abstract][Full Text] [Related]
4. The insulin-like growth factor axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model.
Kaplan PJ; Mohan S; Cohen P; Foster BA; Greenberg NM
Cancer Res; 1999 May; 59(9):2203-9. PubMed ID: 10232609
[TBL] [Abstract][Full Text] [Related]
5. Raf kinase inhibitor protein (RKIP) deficiency decreases latency of tumorigenesis and increases metastasis in a murine genetic model of prostate cancer.
Escara-Wilke J; Keller JM; Ignatoski KM; Dai J; Shelley G; Mizokami A; Zhang J; Yeung ML; Yeung KC; Keller ET
Prostate; 2015 Feb; 75(3):292-302. PubMed ID: 25327941
[TBL] [Abstract][Full Text] [Related]
6. Increased expression of MUC18 correlates with the metastatic progression of mouse prostate adenocarcinoma in the TRAMP model.
Wu GJ; Fu P; Chiang CF; Huss WJ; Greenberg NM; Wu MW
J Urol; 2005 May; 173(5):1778-83. PubMed ID: 15821586
[TBL] [Abstract][Full Text] [Related]
7. Androgen-independent prostate cancer progression in the TRAMP model.
Gingrich JR; Barrios RJ; Kattan MW; Nahm HS; Finegold MJ; Greenberg NM
Cancer Res; 1997 Nov; 57(21):4687-91. PubMed ID: 9354422
[TBL] [Abstract][Full Text] [Related]
8. Role of high expression levels of CXCR4 in tumor growth, vascularization, and metastasis.
Darash-Yahana M; Pikarsky E; Abramovitch R; Zeira E; Pal B; Karplus R; Beider K; Avniel S; Kasem S; Galun E; Peled A
FASEB J; 2004 Aug; 18(11):1240-2. PubMed ID: 15180966
[TBL] [Abstract][Full Text] [Related]
9. Down-regulation of CD9 expression during prostate carcinoma progression is associated with CD9 mRNA modifications.
Wang JC; Bégin LR; Bérubé NG; Chevalier S; Aprikian AG; Gourdeau H; Chevrette M
Clin Cancer Res; 2007 Apr; 13(8):2354-61. PubMed ID: 17406028
[TBL] [Abstract][Full Text] [Related]
10. Novel syngeneic pseudo-orthotopic prostate cancer model: vascular, mitotic and apoptotic responses to castration.
Frost GI; Lustgarten J; Dudouet B; Nyberg L; Hartley-Asp B; Borgström P
Microvasc Res; 2005 Jan; 69(1-2):1-9. PubMed ID: 15797254
[TBL] [Abstract][Full Text] [Related]
11. Colocalisation of CD9 and mortalin in CD9-induced mitotic catastrophe in human prostate cancer cells.
Zvereff V; Wang JC; Shun K; Lacoste J; Chevrette M
Br J Cancer; 2007 Oct; 97(7):941-8. PubMed ID: 17848953
[TBL] [Abstract][Full Text] [Related]
12. Phellodendron amurense bark extract prevents progression of prostate tumors in transgenic adenocarcinoma of mouse prostate: potential for prostate cancer management.
Ghosh R; Graham H; Rivas P; Tan XJ; Crosby K; Bhaskaran S; Schoolfield J; Banu J; Fernandes G; Yeh IT; Kumar AP
Anticancer Res; 2010 Mar; 30(3):857-65. PubMed ID: 20393007
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of CXCR4/CXCL12 signaling axis by ursolic acid leads to suppression of metastasis in transgenic adenocarcinoma of mouse prostate model.
Shanmugam MK; Manu KA; Ong TH; Ramachandran L; Surana R; Bist P; Lim LH; Kumar AP; Hui KM; Sethi G
Int J Cancer; 2011 Oct; 129(7):1552-63. PubMed ID: 21480220
[TBL] [Abstract][Full Text] [Related]
14. Fibroblast growth factor 2 promotes tumor progression in an autochthonous mouse model of prostate cancer.
Polnaszek N; Kwabi-Addo B; Peterson LE; Ozen M; Greenberg NM; Ortega S; Basilico C; Ittmann M
Cancer Res; 2003 Sep; 63(18):5754-60. PubMed ID: 14522896
[TBL] [Abstract][Full Text] [Related]
15. Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model.
Foster BA; Gingrich JR; Kwon ED; Madias C; Greenberg NM
Cancer Res; 1997 Aug; 57(16):3325-30. PubMed ID: 9269988
[TBL] [Abstract][Full Text] [Related]
16. Over-expression of CD9 does not affect in vivo tumorigenic or metastatic properties of human prostate cancer cells.
Zvieriev V; Wang JC; Chevrette M
Biochem Biophys Res Commun; 2005 Nov; 337(2):498-504. PubMed ID: 16198313
[TBL] [Abstract][Full Text] [Related]
17. A null-mutation in the Znt7 gene accelerates prostate tumor formation in a transgenic adenocarcinoma mouse prostate model.
Tepaamorndech S; Huang L; Kirschke CP
Cancer Lett; 2011 Sep; 308(1):33-42. PubMed ID: 21621325
[TBL] [Abstract][Full Text] [Related]
18. Oral consumption of green tea polyphenols inhibits insulin-like growth factor-I-induced signaling in an autochthonous mouse model of prostate cancer.
Adhami VM; Siddiqui IA; Ahmad N; Gupta S; Mukhtar H
Cancer Res; 2004 Dec; 64(23):8715-22. PubMed ID: 15574782
[TBL] [Abstract][Full Text] [Related]
19. Deletion of tetraspanin CD9 diminishes lymphangiogenesis in vivo and in vitro.
Iwasaki T; Takeda Y; Maruyama K; Yokosaki Y; Tsujino K; Tetsumoto S; Kuhara H; Nakanishi K; Otani Y; Jin Y; Kohmo S; Hirata H; Takahashi R; Suzuki M; Inoue K; Nagatomo I; Goya S; Kijima T; Kumagai T; Tachibana I; Kawase I; Kumanogoh A
J Biol Chem; 2013 Jan; 288(4):2118-31. PubMed ID: 23223239
[TBL] [Abstract][Full Text] [Related]
20. Chronic low dose ethanol induces an aggressive metastatic phenotype in TRAMP mice, which is counteracted by parthenolide.
Morel KL; Ormsby RJ; Solly EL; Tran LNK; Sweeney CJ; Klebe S; Cordes N; Sykes PJ
Clin Exp Metastasis; 2018 Oct; 35(7):649-661. PubMed ID: 29936575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
